CagriSema
(Cagrilintide + Semaglutide Research Blend)
CagriSema is an advanced combination of two investigational compounds—Cagrilintide, a long-acting amylin analog, and Semaglutide, a GLP-1 receptor agonist. Together, these compounds are being studied for their synergistic effects on appetite suppression, energy balance, and metabolic regulation. Research areas include:
-
Appetite and Caloric Intake Control
CagriSema is being explored for its dual-action impact on satiety, hunger signaling, and portion control through central and gastrointestinal pathways. -
Weight Loss and Body Composition
Studies are examining its potential to produce superior fat mass reduction compared to single-agent incretin therapies. -
Glycemic and Hormonal Balance
The blend is under investigation for its ability to improve insulin sensitivity, stabilize postprandial glucose, and influence metabolic hormone cascades.
How It Works
CagriSema combines two complementary mechanisms:
-
Cagrilintide targets amylin receptors in the brain to delay gastric emptying, reduce food intake, and enhance satiety signaling.
-
Semaglutide activates GLP-1 receptors, supporting insulin secretion, appetite suppression, and glucose regulation.
Together, they offer a broader spectrum of metabolic signaling, making this dual-agonist approach a compelling research candidate in the study of obesity, type 2 diabetes, and appetite-related disorders.
⚠️ Important Notice:
This product is sold strictly for laboratory research purposes only. It is not for human or animal use, and not for therapeutic or diagnostic applications.
By purchasing, you confirm that you are a qualified individual using this product in accordance with all applicable laws and research regulations.
